Skip to main content
. 2022 Nov 9;141(6):673–677. doi: 10.1182/blood.2022017386

Table 1.

Population characteristics by PML reporting status among patients treated with CD19-CAR-T and reported to FAERS

PML reports (n = 11) Non-PML reports (n = 4026) P value
Reporting region
 Americas 5/11 (45.5) 3291/4025 .010
 Europe 5/11 (45.5) 618/4025
 Asia 1/11 (9.0) 60/4025
 Australia 0/11 (0.00) 56/4025
Reporter
 Health professional 10/11 (90.9) 3559/3914 (90.9) >.99
 Consumer/lawyer 1/11 (9.1) 355/3914 (9.1)
Event year
 2018 0/8 (0.0) 729/2429 (29.9) .040
 2019 2/8 (25.0) 934/2429 (38.5)
 2020 6/8 (75.0) 705/2429 (29.0)
 2021 0/8 (0.0) 61/2429 (2.5)
Age, y
 Median (IQR) 63 (58-67) n = 10 57 (28-67) n = 2882 .163
Sex
 Female 7/10 (70.0) 1254/3255 (38.5) .052
 Male 3/10 (30.0) 2001/3255 (61.5)
Product
 Axicabtagene-ciloleucel 7/11 (63.6) 2331/4026 (57.9) .770
 Tisagenlecleucel 4/11 (36.4) 1695/4026 (42.1)
Indication
 NHL 9/10 (90.0) 2474/3316 (74.6) .544
 ALL 1/10 (10.0) 791/3316 (23.9)
 Other 0/10 (0.0) 51/3316 (1.5)
Time to AE onset, mo
 Median (IQR) 8 (8-15) n = 10 0.13 (0.03-0.33) n = 1983 <.001
 Min-max 6-31 n = 10 0-82 n = 1983
Reported fatality rate 7/9 (77.8) 906/3831 (23.6) <.001

All values are n (%) unless otherwise indicated.

IQR, interquartile range.

Only cases reported before 31 March 2021 were included.